Considerable progress has been made in improving the control of chemotherapy-induced emesis. The impact of available antiemetic options for patients receiving stem cell transplants is unclear, as few prospective data have been collected. We prospectively evaluated antiemetic outcome in patients receiving stem cell transplantation over a 7-day period following the initiation of chemotherapy. The primary endpoints were the number of emetic episodes and the extent of nausea measured on a four-point scale. Eighty-two patients were evaluated. Ninety-five percent of patients had nausea during the first week of treatment; 80% had at least one emetic episode. The percentage of patients with emesis was as follows: day 1: 13%, day 2: 21%, day 3: 30%, day 4: 38%, day 5: 44%, day 6: 39%, day 7: 18%. In multivariate analysis, gender, emesis with prior chemotherapy, history of morning or motion sickness, type of transplant (auto vs allo), use of total body irradiation, or use of dexamethasone did not effect emesis control. Most patients receiving high-dose chemotherapy experience incompletely controlled emesis. Control of nausea and emesis progressively worsened with each subsequent day following initiation of chemotherapy, reaching a nadir on day 5. New treatment approaches are needed to improve emesis control in this patient population. Bone Marrow Transplantation (2001) 28, 1061-1066. Keywords: nausea; bone marrow transplantation Myeloablative chemotherapy and radiotherapy followed by autologous or allogeneic stem cell transplantation have been shown to be curative for certain hematologic malignancies, aplastic anemia, and genetic disorders.
icity and improve tolerance of autologous and allogeneic stem cell transplantation. [4] [5] [6] [7] From the patient's standpoint, two of the most feared adverse effects of chemotherapy are treatment-induced nausea and vomiting. 8, 9 Considerable progress has been made in the control of nausea and vomiting for patients receiving standard doses of chemotherapy. The use of 5-hydroxytryptamine-3 (5HT3) antagonists, such as dolasetron, granisetron and ondansetron, have contributed significantly to the control of nausea and vomiting in patients receiving moderately and highly emetogenic chemotherapy. [10] [11] [12] [13] The great majority of patients receiving emetogenic chemotherapy at standard doses should achieve complete control of emesis at the present time.
A number of patient and treatment-related factors predictive for the development of chemotherapy-induced emesis have been defined. These include age, gender, ethanol consumption history, and the intrinsic emetogenicity of the chemotherapy agents.
14 Also of importance is chemotherapy dose. The emetogenicity of a number of chemotherapy agents such as cisplatin and cyclophosphamide increases with increasing dose. 15 The outcome of antiemetic therapy has not been well studied in the setting of highdose chemotherapy with hematopoietic stem cell support. Trovato et al 16 evaluated antiemetic outcome in 59 patients receiving highly emetogenic high-dose chemotherapy with peripheral blood stem cell rescue. Forty-one of the patients were reviewed retrospectively. By day 5 of evaluation, 35 (76%) of 46 patients had grade 2-3 nausea and 23 (50%) had vomiting. Similarly, Perez et al 17 retrospectively reviewed antiemetic outcome in 24 patients receiving highdose chemotherapy with bone marrow transplantation. Twenty-three (96%) patients experienced antiemetic failure within the first 3 days. Apart from retrospective series, there has been a paucity of well-conducted prospective trials to more rigorously assess antiemetic outcome in the high-dose chemotherapy setting.
To more accurately gauge the extent of the current problem and to serve as a frame of reference for potential new treatment approaches, we examined prospectively in this study the incidence and pattern of nausea and vomiting in patients receiving autologous and allogeneic stem cell transplantation, in association with high-dose chemotherapy.
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Patients and methods
Patients
All patients age 18 and over receiving autologous, allogeneic, or unrelated stem cell transplant for malignancy at UMass Memorial Health Care between October 1997 and April 2000 were invited to participate in the study. Any recipient of an inpatient transplant was eligible. The study was discussed at the pre-transplant family conference and all subjects signed an informed consent form approved by the Human Subjects Committee of the University of Massachusetts Medical School.
Study design
This study was a single center, prospective study with a 7-day efficacy evaluation period following the start of chemotherapy. A 7-day questionnaire was used to capture information on nausea and emesis. All study subjects were inpatients for the duration of the study and were directly observed by trained bone marrow transplant nurses for episodes of emesis. Patients were routinely checked by nursing staff every 2 h, and patients were asked to report all episodes of emesis. Nausea was recorded on a daily basis by patients and graded by a categorical scale of 1-4 (1 ϭ none; 2 ϭ mild, did not interfere with normal daily life; 3 ϭ moderate, interfered with normal daily life; 4 ϭ severe, bedridden because of nausea). Patients coded their nausea at 6 pm each day. Additional information recorded included all drugs administered, their doses, and the timing of any antiemetics employed, as well as various demographic and treatment features. These features included the age, gender, diagnosis, and performance status of the patient, prior chemotherapy/radiotherapy, emesis with prior chemotherapy, prior motion sickness, morning sickness, and alcohol use. The type of graft and the conditioning regimen were also recorded. Side-effects of antiemetics were also recorded. All nurses were instructed in the administration of the study questionnaire and all questionnaires were reviewed by the principal investigator.
Statistics
Patient gender, prior chemotherapy, prior motion sickness, and prior morning sickness, type of transplantation, total body irradiation (TBI) and use of dexamethasone were studied as predictive factors for the emetic outcomes. In univariate analysis, Fisher's exact test was used to test the difference of proportional distribution of emesis among different categories of all these seven factors. For multivariate analysis, a logistic regression model was fitted to investigate the independent effects of patient gender, prior chemotherapy, prior motion sickness, type of transplantation, TBI, and the use of dexamethasone on the development of nausea and emesis. 18 All statistical analyses were conducted with SAS 8.0.
Results
Patient characteristics
Eighty-two patients enrolled in the study. Patient characteristics are outlined in Table 1 . Thirty-five patients were male, and 47 female. The most common diagnosis was lymphoma, followed by leukemia and myeloma. Nineteen patients (23%) had a history of motion sickness and seven (9%) had a history of heavy alcohol use (defined as five or more drinks a day). Forty-three percent of the parous females reported morning sickness with at least one pregnancy. Seventy-seven patients had received chemotherapy prior to transplant; 47 patients (61%) reported emesis with their prior chemotherapy.
Conditioning regimens
Sixteen patients were conditioned with a TBI-containing regimen and 66 patients without TBI. The dose of TBI was 12 Gy and administered in eight fractions. Conditioning regimens are outlined in Table 2 . Detailed schedule and doses of the conditioning regimens are listed in the Appendix. The most common chemotherapy combination was cyclophosphamide/etoposide/BCNU used in lymphoma patients (29%), followed by thiotepa/melphalan/cyclophosphamide for myeloma patients (15%). Twenty-six patients (32%) received an allograft, six from an unrelated donor and 20 from a sibling donor; 56 patients (68%) received an autograft.
Antiemetic treatment
All patients received standard pre-and post-transplant supportive care, as per the protocols at UMass Memorial Health Care. Prior to May 1998, all patients received prophylactic ondansetron at a dose of 1 mg/h continuous intravenous infusion, starting 1 h prior to chemotherapy and continuing until 24 h after chemotherapy. In May 1998, an institutional decision was made to switch antiemetics to granisetron/dexamethasone, at a dose of 2 mg granisetron and 10 mg dexamethasone every 12 h starting 1 h prior to chemotherapy and continuing until 24 h after last dose of chemotherapy. Supplemental lorazepam, perphenazine/ diphenhydramine were added on an individual basis, according to the needs of each patient. Antiemetic usage is outlined in Table 2 .
Control of nausea
Nausea control is outlined in Figure 1 , which demonstrates the percentage of patients with no nausea during each day of the study period. Nausea was graded by patients on a daily basis for 6 days from the start of conditioning using a scale of 1-4, 1 ϭ none, 2 ϭ mild, 3 ϭ moderate, 4 ϭ severe nausea. Four patients (5%) reported no nausea during the study period. Nausea was most severe on day 5; 68 patients (83%) reported nausea on day 5.
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Control of emesis
Emesis control is outlined in Figure 2 , which shows the percentage of patients with no emesis at various times during the study period. Sixteen patients (20%) reported no emesis during the entire study period. Emesis was most pronounced on day 5, with 36 patients (44%) experiencing emesis on day 5. Emesis was most severe on day 5, regardless of the timing of cyclophosphamide.
Effect of study variables on emesis
Patient gender, prior chemotherapy, prior motion sickness, the type of graft, the use of TBI in conditioning, the use of dexamethasone, emesis with prior chemotherapy, and prior morning sickness were studied as predictive factors for the development of emesis, as demonstrated in Table 3 . None of these seven factors were significant predictors of emesis. Patients who received dexamethasone as part of the antiemetic regimen had a trend to less emesis, but this difference did not reach statistical significance (P ϭ 0.28). There was no significant difference in emesis outcome by different conditioning regimens.
Discussion
Tremendous progress has been made over the last 10 years in improving the control of nausea and vomiting induced For some variables the total does not sum to 82 due to missing data. Adjusted odds ratios and their 95% confidence interval (CI) were derived from a logistic regression model that included gender, prior chemotherapy, history of prior motion sickness, type of transplantation, total body irradiation and use of decadron. Logistic regression was performed for 76 subjects with complete information on study variables. Prior morning sickness was examined only among women who had a pregnancy.
by standard-dose chemotherapy. [10] [11] [12] [13] The combination of a 5-HT3 receptor antagonist and a corticosteroid represent the current standard of care in the prevention of emesis with moderate to highly emetogenic chemotherapy. 19 For patients receiving high-dose chemotherapy or chemo/ radiotherapy regimens in association with hematopoietic stem cell support, a number of studies suggest that antiemetic control may be a greater challenge in this setting. 17, [20] [21] [22] [23] [24] [25] In the current prospective trial, we have clearly demonstrated that despite the use of standard prophylactic treatments, antiemetic control is indeed suboptimal for patients receiving allogeneic or autologous hematopoietic stem cell transplants and appears to be inferior to the results obtained with standard-dose chemotherapy. Limitations of the study include the diverse conditioning regimens, antiemetic treatments, and small sample size. Eighty percent of patients experienced some degree of emesis during the study period and nausea was virtually a universal experience with only 5% of patients noting no nausea. We also demonstrated that control of emesis and nausea progressively worsens with each subsequent day after the initiation of chemotherapy, reaching a peak at 5 days with a gradual lessening of symptoms thereafter. This pattern of symptoms is very reminiscent of the pattern of emesis noted with conventionaldose emetogenic chemotherapy regimens when administered over consecutive days. The observation period defined for the current study was somewhat arbitrarily chosen, given the lack of standard methodology for antiemetic assessment in this setting. Nevertheless, it would appear to have encompassed the primary period of risk for nausea and vomiting.
A number of factors known to be predictive for the development of emesis with standard-dose chemotherapy were evaluated in our patient population.
14 Other prospective studies did not analyze these predictive factors. 22, 23 Of note, none were found to have a significant impact. There was a trend toward less emesis in patients receiving dexamethasone and perhaps this would have achieved significance with a larger patient sample. This remains an important area for future investigation given the current controversy among transplant physicians about the use of corticosteroids as antiemetics in this patient population. A recent meta-analysis has documented the value of dexamethasone in the prevention of acute and delayed emesis in patients receiving moderately or highly emetogenic standard-dose chemotherapy. 26 Clearly, there is a need for larger studies to further define risk factors for high-dose chemoradiotherapy induced emesis.
More effective approaches to controlling nausea and vomiting in patients undergoing hematopoietic transplants need to be identified. It appears unlikely that currently available antiemetics offer significant hope for better emesis control. New classes of antiemetics with novel mechanisms of action would be of potential interest. One new group currently undergoing evaluation as antiemetics with conventional-dose chemotherapy is the neurokinin 1 receptor antagonists. These are nonpeptide compounds which are capable of selectively antagonizing the action of the tachykinin substance P at the neurokinin 1 receptor. Preclinical studies have demonstrated that these agents are capable of blocking the development of emesis due to a wide spectrum of stimuli including cisplatin. [27] [28] [29] Early clinical trials have confirmed the activity of these agents in treating cisplatin-induced emesis. In combination with a 5-HT3 receptor antagonist and dexamethasone, they improve the control of nausea and vomiting developing in the first 24 h after chemotherapy (acute emesis) and are also active in lessening emesis during the 5 days after chemotherapy (delayed emesis). 30, 31 It is the latter capability of these agents that may have the greatest relevance to the highdose chemotherapy setting. The results of clinical trials with these agents in patients receiving hematopoietic stem cell transplants are awaited with great interest.
